ArticleBMJ open2026
Association of systolic blood pressure time in target range and all-cause mortality in patients with atherosclerotic cardiovascular disease: an analysis of a prospective cohort study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the association between systolic blood pressure time in target range (SBP-TTR) and the risk of all-cause mortality in patients with atherosclerotic cardiovascular disease (ASCVD).
designAnalysis of data from a prospective cohort.
settingThis study used data from the Kailuan Study. Participants diagnosed with ASCVD from 11 hospitals affiliated with the Kailuan Group in Tangshan, China were included in the analysis.
participantsWe included 6732 participants who developed ASCVD between 1 July 2006 and 31 December 2013, and who had two or more blood pressure measurements recorded between the ASCVD diagnosis date and 31 December 2017. All participants were followed up until 31 December 2022. OUTCOME MEASURES: SBP-TTR was defined as the proportion of time during which SBP remained within the target range, calculated using the linear interpolation method. Participants were stratified into five SBP-TTR categories: 0%, >0% to <25%, 25% to <50%, 50% to <75% and ≥75%. Associations between SBP-TTR categories and all-cause mortality were evaluated.
resultsWhen the target SBP range was defined as 120-140 mm Hg, compared with the SBP-TTR=0% group, the multivariable-adjusted HRs (95% CIs) for all-cause mortality were 0.92 (0.78 to 1.07), 0.82 (0.72 to 0.94), 0.79 (0.68 to 0.92) and 0.76 (0.65 to 0.89) for the SBP-TTR groups of <25%, 25% to <50%, 50% to <75% and ≥75%, respectively. For each SD increase in SBP-TTR, the risk of all-cause mortality decreased, with a multivariable-adjusted HR of 0.90 (95% CI 0.85 to 0.95). The inverse association between SBP-TTR and all-cause mortality was more pronounced in younger participants (aged <67 years) (p for interaction=0.008).
conclusionsThis study demonstrated a significant inverse association between SBP-TTR and all-cause mortality among patients with ASCVD. The association between maintaining SBP within the 120-140 mm Hg target range and reduced mortality was more evident in younger individuals. These findings suggest that sustained and stable blood pressure control may improve long-term survival in patients with ASCVD. TRIAL REGISTRATION NUMBER: ChiCTR-TNC-11001489.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.